Akeso, Inc. (09926.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 92.05

From 52W high−40.07%

Volume8.66M

Market capHKD 81.71B

P/E (TTM)—

P/S (TTM)20.6x

Div yield—

Key dataSep 18, 2026

Open

HKD 92.05

From 52W high

−40.07%

Volume

8.66M

Market cap

HKD 81.71B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−79.9x

P/E (TTM)

—

RSI (14)

46.1

MomentumView details →

1D Return

−0.28%

YTD Return

−19.91%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−79.9x

EV/Sales

19.3x

P/S (TTM)

20.6x

P/B (TTM)

8.2x

ProfitabilityView details →

Gross Margin

76.04%

Net Margin

−28.02%

EBITDA Margin

−24.17%

ROE (TTM)

−11.22%

ROA (TTM)

−5.87%

Asset Turnover

0.21x

GrowthView details →

Revenue YoY

+35.34%

EPS YoY

−8.33%

FCF YoY

—

Revenue CAGR 3Y

+52.61%

EPS CAGR 3Y

−100.00%

EBITDA YoY

−16.65%

MomentumView details →

1D Return

−0.28%

YTD Return

−19.91%

1Y Return

−30.22%

RSI (14)

46.1

vs 50D SMA

−4.65%

vs 200D SMA

−17.55%

Capital & dividendView details →

Debt/Equity

0.59x

Current Ratio

4.01x

Quick Ratio

3.62x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.53

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

HKD 0.00

Avg Surprise (4Q)

—

Rev Surprise

−23.98%

Financials snapshotView financials →

Revenue (TTM)

5.91B

Net Income (TTM)

−1.80B

Op. CF (TTM)

−969.59M

Next earningsMar 31, 2027 →

Latest newsMore news →

Akeso announced that its AK112 (brand name Yidafang) reported significantly positive overall survival results in the registrational Phase III HARMONI-2 trial for first-line treatment of PD-L1-positive NSCLC at WCLC.4d ago

Akeso announced that its independently developed dual-antibody ADC drug AK158D1 (EGFR/Trop2) received approval from the Center for Drug Evaluation of the National Medical Products Administration to conduct a Phase I clinical study for the treatment of advanced malignant solid tumors.4d ago

Similar companies

Regeneron Pharmaceuticals, Inc.REGN Genscript Biotech Corporation01548.HK Innovent Biologics, Inc.01801.HK Sino Biopharmaceutical Limited01177.HK MedPacto, Inc.235980.KQ Vaxcell-Bio Therapeutics Co., Ltd.323990.KQ Find similar companies →

Latest newsMore news →

Akeso announced that its AK112 (brand name Yidafang) reported significantly positive overall survival results in the registrational Phase III HARMONI-2 trial for first-line treatment of PD-L1-positive NSCLC at WCLC.4d ago Akeso announced that its independently developed dual-antibody ADC drug AK158D1 (EGFR/Trop2) received approval from the Center for Drug Evaluation of the National Medical Products Administration to conduct a Phase I clinical study for the treatment of advanced malignant solid tumors.4d ago Akeso's AK112 (ivonescimab) presented Phase III HARMONI-2 trial data in first-line PD-L1-positive non-small cell lung cancer versus Keytruda at WCLC 2026.4d ago